Daclatasvir (BMS-790052)是一种高效的口服HCV NS5A抑制剂,它还能抑制有机阴离子转运多肽OATP1B和OATP1B3。
|
英文别名 (English Synonym) |
Daclatasvir (BMS-790052) |
|
中文名称 (Chinese Name) |
达拉他韦 |
|
靶点 (Target) |
HCV Protease |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
1009119-64-5 |
|
分子式 (Formula) |
C40H50N8O6 |
|
分子量 (Molecular Weight) |
738.88 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Ascher DB, Wielens J, Nero TL, Doughty L, Morton CJ, Parker MW. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23,4:4765. doi: 10.1038/srep04765. PMID: 24755925, PMCID: PMC3996483.[2]Lee SH, Moon JS, Pak BY, Kim GW, Lee W, Cho H, Kim S, Kim SJ, Oh JW. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20,8(1):12469. doi: 10.1038/s41598-018-30460-3. PMID: 30127498, PMCID: PMC6102265.
